Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing Michel FarnierPoint Médical, Dijon, FranceAbstract: Mixed dyslipidemia is a common lipid disorder characterized by the presence of an atherogenic lipoprotein phenotype due to abnormalities in various atherogenic and antiatherogenic lipoproteins. Despite the link between the decrease of LDL-cholesterol by statin treatment and the prevention of cardiovascular disease, a high residual risk is observed in statin trials. This residual risk is partly explained by lipoprotein abnormalities other than LDL. Fenofibrate exerts a favorable effect on the atherogenic lipid profile of mixed dyslipidemia and can effectively reduce cardiovascular disease in patients with mixed dyslipidemia. Fenofibrate may offer important treatment alternatives as a second-line therapy in several circumstances: in combination with a statin for patients with mixed dyslipidemias not at goals on statin monotherapy; in monotherapy for patients intolerant or with contraindication to statin therapy; and in combination with other drugs (ezetimibe, colesevelam) for patients with mixed dyslipidemias, known intolerance, or contraindication to statin and not at goals on fenofibrate monotherapy. However, the role of fenofi brate-statin therapy and of other therapies involving fenofibrate in cardiovascular risk reduction strategies remains to be established.Keywords: fenofibrate, mixed dyslipidemia, triglycerides, LDL-cholesterol, HDL-cholesterol
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881 · cited 4×
“It has been shown that gemfi brozil increased plasma homocysteine less than fenofi brate (Dierkes et al 2003; Syvanne et al 2004) and this difference could explain the better clinical benefi t of gemfi brozil in the VA-HIT (Robins et al 2001; Rubins et al 2002) and HHS (Frick et al 1987).”
BackgroundInfluentialHigh-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162 · cited 3×
“All rights reserved Vascular Health and Risk Management 2008:4(5) 991–1000 991”
BackgroundNordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408 · cited 2×
“A recent meta-analysis of 29 prospective studies enrolling 262,525 subjects indicated a strong and highly signifi cant association between TG values and CHD risk (Sarwar et al 2007).”
BackgroundChinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., et al. (2001) · Nature Medicine · doi:10.1038/83348 · Cited by 1,170 · cited 1×
“All these effects contribute to the increase of plasma HDL-C concentrations (Guerin et al 1996; Chinetti et al 2001; Mardones et al 2003; Fruchart and Duriez 2006).”
BackgroundPrimary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus
Buse, J. B., Ginsberg, H. N., Bakris, G. L., Clark, N. G., Costa, F., Eckel, R., Fonseca, V., Gerstein, H. C., Grundy, S., Nesto, R. W., et al. (2007) · Diabetes Care · doi:10.2337/dc07-9917 · Cited by 1,055 · cited 1×
“Clinical effi cacy in combination with statins Guidelines suggest both fi brates and niacin as additions to statin therapy in high risk patients with persistently low levels of HDL-C and elevated triglycerides (Grundy et al 2004a; Buse et al 2007; The Task Force on Diabetes 2007).”
BackgroundIncidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875 · cited 2×
“Moreover the risk was particularly elevated when cerivastatin was use in combination with gemfi brozil (Chang et al 2004; Graham et al 2004; Jones and Davidson 2005).”
BackgroundGrundy, S. M., Hansen, B., Smith, S. C., Cleeman, J. I., Kahn, R. A., & Participants, F. C. (2004) · Circulation · doi:10.1161/01.cir.0000112379.88385.67 · Cited by 864
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
Cannon, C. P., Steinberg, B. A., Murphy, S. A., Mega, J. L., & Braunwald, E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.070 · Cited by 770
Ridker, P. M., Rifai, N., Cook, N. R., Bradwin, G., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.3.326 · Cited by 744
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods
Buse, J. B. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.003 · Cited by 661
Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586 · cited 2×
“It has been shown that gemfi brozil increased plasma homocysteine less than fenofi brate (Dierkes et al 2003; Syvanne et al 2004) and this difference could explain the better clinical benefi t of gemfi brozil in the VA-HIT (Robins et al 2001; Rubins et al 2002) and HHS (Frick et al 1987).”
BackgroundLipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
Kastelein, J. J. P., van der Steeg, W. A., Holme, I., Gaffney, M., Cater, N. B., Barter, P., Deedwania, P., Olsson, A. G., Boekholdt, S. M., Demicco, D. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.713438 · Cited by 478 · cited 1×
“More recently, in a post hoc analysis of TNT and IDEAL trials (Kastelein et al 2008), on-statin treatment levels of non-HDL-C and apolipoprotein B were more closely associated with cardiovascular outcome than LDL-C levels, supporting the use of non-HDL-C as a novel treatment target.”
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds
Birjmohun, R. S., Hutten, B. A., Kastelein, J. J. P., & Stroes, E. S. G. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.031 · Cited by 429 · cited 3×
“The most frequent adverse effects were gastrointestinal symptoms, skin reactions and musculoskeletal symptoms (Birjmohun et al 2005).”
BackgroundMethodSafety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
Jones, P. H., & Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.08.076 · Cited by 387 · cited 3×
“Moreover the risk was particularly elevated when cerivastatin was use in combination with gemfi brozil (Chang et al 2004; Graham et al 2004; Jones and Davidson 2005).”
BackgroundGlucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
Prueksaritanont, T., Subramanian, R., Fang, X., Ma, B., Qiu, Y., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.505 · Cited by 344 · cited 4×
“The author reports having received grant/research support and/or honoraria from a consultant for Astra-Zeneca, Genfi t, Vascular Health and Risk Management 2008:4(5)998 Genzyme, Kowa, Merck and Co, Merck-Schering-Plough, Novartis, Pfizer, Roche, Sanofi-Aventis, Solvay, and Takeda.”
BackgroundInfluentialGrundy, S. M., Vega, G. L., Yuan, Z., Battisti, W. P., Brady, W. E., & Palmisano, J. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.10.012 · Cited by 309 · cited 4×
“Finally, clinical trial data have not reported an increased risk of myopathy with various statins combined to fenofi brate (Ellen and McPherson 1998; Farnier and Dejager 2000; Athyros et al 2002; Martin et al 2003; Vega et al 2003; Durrington et al 2004; Grundy et al 2005).”
BackgroundMethodResultInfluentialAnsquer, J.-C., Foucher, C., Rattier, S., Taskinen, M.-R., & Steiner, G. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.11.004 · Cited by 264
Fenofibrate Increases Creatininemia by Increasing Metabolic Production of Creatinine
Hottelart, C., El Esper, N., Rose, F., Achard, J.-M., & Fournier, A. (2002) · Nephron · doi:10.1159/000064083 · Cited by 186
Keating, G. M., & Croom, K. F. (2007) · Drugs · doi:10.2165/00003495-200767010-00013 · Cited by 169
The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy
Fazio, S., & Linton, M. F. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0104-8 · Cited by 118
Bergman, A. J., Murphy, G., Burke, J., Zhao, J. J., Valesky, R., Liu, L., Lasseter, K. C., He, W., Prueksaritanont, T., Qiu, Y., et al. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004268044 · Cited by 97 · cited 1×
“But fenofi brate has not signifi cant effect on the pharmacokinetics of various statins (Pan et al 2000; Martin et al 2003; Bergman et al 2004, Gustavson et al 2005).”
BackgroundGinsberg, H. N., Bonds, D. E., Lovato, L. C., Crouse, J. R., Elam, M. B., Linz, P. E., O’Connor, P. J., Leiter, L. A., Weiss, D., Lipkin, E., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.024 · Cited by 95
Farnier, M., Roth, E., Gil-Extremera, B., Mendez, G. F., Macdonell, G., Hamlin, C., Perevozskaya, I., Davies, M. J., Kush, D., & Mitchel, Y. B. (2007) · American Heart Journal · doi:10.1016/j.ahj.2006.10.031 · Cited by 83
Self-citationGenest, J., Frohlich, J., & Steiner, G. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.12.022 · Cited by 51 · cited 1×
“In DAIS, the increase of homocysteine did not alter the benefi cial effect of fenofi brate (Genest et al 2004).”
Background
Cited by
Ali, K. M., Wonnerth, A., Huber, K., & Wojta, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02081.x · Cited by 292
Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Toth, P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s104369 · Cited by 237
Pemafibrate Tends to have Better Efficacy in Treating Dyslipidemia than Fenofibrate
Wang, H., Li, H., Zhou, Y., Liu, J., Wang, F., & Zhao, Q. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612825666191126102943 · Cited by 11
Fibrates : Do They Still Have a Role in Therapy in 2025?
Pirillo, A., Zambon, A., & Catapano, A. L. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01379-8 · Cited by 4
“Fibrates have historically been used to address this phenotype [2 – 5 ], but interest has declined due to neutral lipoproteins (VLDL), and enhanced clearance of triglyceride-rich lipoproteins [6] (Fig.”
Metadata
- Authors
- Farnier, M.
- Venue
- Vascular Health and Risk Management
- Publisher
- Informa UK Limited
- Published
- 2008-10
- Volume
- Volume 4
- Issue
- 5
- Pages
- 991-1000
- ISSN
- 1176-6344 (ISSN-L)
- 1178-2048
- OpenAlex
- W1827278273
- Cited by
- 63
- References
- 31
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.